Article

You have full text access to this OnlineOpen article

Chemical synthesis and biotinylation of the thrombospondin domain TSR2

  1. Theresa K. Tiefenbrunn1,2,
  2. Philip E. Dawson1,2,*

Article first published online: 16 MAR 2009

DOI: 10.1002/pro.107

Issue

Protein Science

Protein Science

Volume 18, Issue 5, pages 970–979, May 2009

Additional Information

How to Cite

Tiefenbrunn, T. K. and Dawson, P. E. (2009), Chemical synthesis and biotinylation of the thrombospondin domain TSR2. Protein Science, 18: 970–979. doi: 10.1002/pro.107

Author Information

  1. 1

    Department of Cell Biology, The Scripps Research Institute, La Jolla, California 92037

  2. 2

    Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037

*The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037

Publication History

  1. Issue published online: 21 APR 2009
  2. Article first published online: 16 MAR 2009
  3. Accepted manuscript online: 16 MAR 2009 12:00AM EST
  4. Manuscript Accepted: 19 FEB 2009
  5. Manuscript Revised: 18 FEB 2009
  6. Manuscript Received: 24 NOV 2008

Funded by

  • NIH. Grant Number: RO1 GM059380

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (455K)

References

  • 1
    Lawler J ( 2002) Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6: 1–12.
    Direct Link:
  • 2
    Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP ( 1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87: 6624–6628.
  • 3
    Zhang XF, Galardi E, Duquette M, Lawler J, Parangi S ( 2005) Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res 11: 5622–5630.
  • 4
    Miao WM, Seng WL, Duquette M, Lawler P, Laus C, Lawler J ( 2001) Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res 61: 7830–7839.
  • 5
    Tucker RP ( 2004) The thrombospondin type 1 repeat superfamily. Int J Biochem Cell Biol 36: 969–974.
  • 6
    Tan K, Duquette M, Liu JH, Dong Y, Zhang R, Joachimiak A, Lawler J, Wang JH ( 2002) Crystal structure of the tsp-1 type 1 repeats: a novel layered fold and its biological implication. J Cell Biol 159: 373–382.
  • 7
    Hofsteenge J, Huwiler KG, Macek B, Hess D, Lawler J, Mosher DF, Peter-Katalinic J ( 2001) C-mannosylation and o-fucosylation of the thrombospondin type 1 module. J Biol Chem 276: 6485–6498.
  • 8
    Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD ( 1999) Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100: 1423–1431.
  • 9
    Silverstein RL ( 2002) The face of tsr revealed: an extracellular signaling domain is exposed. J Cell Biol 159: 203–206.
  • 10
    Schultzcherry S, Lawler J, Murphyullrich JE ( 1994) The type-1 repeats of thrombospondin-1 activate latent transforming growth-factor-beta. J Biol Chem 269: 26783–26788.
  • 11
    Geiger T, Clarke S ( 1987) Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem 262: 785–794.
  • 12
    Schnolzer M, Alewood P, Jones A, Alewood D, Kent SB ( 2007) In situ neutralization in boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int J Pept Res Ther 13: 31–44.
  • 13
    Hackeng TM, Griffin JH, Dawson PE ( 1999) Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology. Proc Natl Acad Sci USA 96: 10068–10073.
  • 14
    Sakakibara S ( 1999) Chemical synthesis of proteins in solution. Biopolymers 51: 279–296.
    Direct Link:
  • 15
    Pennington MW ( 1994) HF cleavage and deprotection procedures for peptides synthesized using a boc/bzl strategy. Methods Mol Biol 35: 41–62.
  • 16
    Garcia-Martin F, Quintanar-Audelo M, Garcia-Ramos Y, Cruz LJ, Gravel C, Furic R, Cote S, Tulla-Puche J, Albericio F ( 2006) Chemmatrix, a poly(ethylene glycol)-based support for the solid-phase synthesis of complex peptides. J Comb Chem 8: 213–220.
  • 17
    Harris KM, Flemer S, Jr, Hondal RJ ( 2007) Studies on deprotection of cysteine and selenocysteine side-chain protecting groups. J Pept Sci 13: 81–93.
    Direct Link:
  • 18
    Erickson BW, Merrifield RB ( 1973) Acid stability of several benzylic protecting groups used in solid-phase peptide synthesis. Rearrangement of o-benzyltyrosine to 3-benzyltyrosine. J Am Chem Soc 95: 3750–3756.
  • 19
    Tam JP, Heath WF, Merrifield RB ( 1983) Sn 1 and sn 2 mechanisms for the deprotection of synthetic peptides by hydrogen fluoride. Studies to minimize the tyrosine alkylation side reaction. Int J Pept Protein Res 21: 57–65.
    Direct Link:
  • 20
    Heath WF, Tam JP, Merrifield RB ( 1986) Improved deprotection of cysteine-containing peptides in HF. Int J Pept Protein Res 28: 498–507.
    Direct Link:
  • 21
    Hallinan EA ( 1991) Formation of a dehydroalanyl residue from s-benzylcysteine upon HF cleavage of a [sar1, cys8]-angiotensin II peptide resin. Int J Pept Protein Res 38: 601–602.
    Direct Link:
  • 22
    Dawson PE ( 1997) Synthesis of chemokines by native chemical ligation. Chemokines 287: 34–45.
  • 23
    Adams JC, Lawler J ( 1994) Cell-type specific adhesive interactions of skeletal myoblasts with thrombospondin-1. Mol Biol Cell 5: 423–437.
  • 24
    Price-Carter M, Gray WR, Goldenberg DP ( 1996) Folding of α-conotoxins. I. Efficient disulfide-coupled folding of mature sequences in vitro. Biochemistry 35: 15537–15546.
  • 25
    Roszmusz E, Patthy A, Trexler M, Patthy L ( 2002) Structural characterization of the second tsp1-module of human thrombospondin. Biochem Biophys Res Commun 296: 156–160.
  • 26
    Huwiler KG, Vestling MM, Annis DS, Mosher DF ( 2002) Biophysical characterization, including disulfide bond assignments, of the anti-angiogenic type 1 domains of human thrombospondin-1. Biochemistry 41: 14329–14339.
  • 27
    Greenfield NJ ( 2004) Analysis of circular dichroism data. Methods Enzymol 383: 282–317.
View Full Article (HTML) Get PDF (455K)